How Iboga Compares

If you're reading this, you've probably already looked into other options. Maybe tried some. This page is an honest comparison — what iboga does that others don't, where others are stronger, and when iboga isn't the right choice.

Iboga vs psilocybin.

Psilocybin is safer. Shorter duration (4–6 hours vs 24–36). Minimal cardiac risk. Legal in some jurisdictions. The experience tends toward emotional opening, perceptual shifts, and connectedness. Good for depression, end-of-life anxiety, and general psychological flexibility.

What psilocybin doesn't do: interrupt opioid withdrawal, reset the dopamine system, or produce the biographical life review that iboga is known for. Psilocybin opens emotional space. Iboga reorganizes the operating system. For someone dealing with depression or existential distress without addiction or deep structural patterns, psilocybin may be the better first step — safer, shorter, more accessible.

Iboga vs ayahuasca.

Ayahuasca carries a rich spiritual tradition. The visionary component is strong — often described as more visual and narrative than iboga. Ayahuasca works primarily through serotonin. Duration is shorter (4–8 hours). The tradition is well-established and widely available.

What ayahuasca doesn't do: no demonstrated anti-addiction pharmacology, no neurological reset, no opioid receptor interaction. Many people who come to iboga have done ayahuasca — sometimes many times — and found that the insights were powerful but didn't stick. That's not a failure of ayahuasca. It's a different medicine doing different work.

Iboga vs ketamine.

Ketamine is legal, medically available, and short-acting (1–2 hours for a session). It has demonstrated antidepressant effects, particularly for treatment-resistant depression. It works through NMDA receptor antagonism — a mechanism it shares with ibogaine, though at different sites and with different effects.

The concern: ketamine has its own addiction potential. Regular use can lead to dependence, bladder damage, and cognitive effects. It's a useful tool for acute depression intervention, but it's not addressing the same structural layer that iboga addresses. And for addiction specifically, using an addictive substance to treat addiction is a complex trade-off.

Iboga vs conventional addiction treatment (MAT).

Medication-Assisted Treatment — methadone, buprenorphine (Suboxone), naltrexone — has a strong evidence base for opioid addiction. MAT works. It saves lives. It should not be dismissed.

The difference is philosophical and mechanical: MAT is maintenance. It manages the addiction by occupying the same receptors the drug of choice occupied. You're stable, but you're still chemically dependent — on the treatment instead of the street drug.

Ibogaine is interruption. It attempts to reset the system to a pre-addicted state, creating a window where chemical dependence is broken and new patterns can be built. Both have roles. The best outcomes often integrate both approaches — ibogaine for breakthrough, behavioral treatment for sustained recovery.

When other approaches are better.